Protagonist Therapeutics
PTGX
70 hedge funds and large institutions have $103M invested in Protagonist Therapeutics in 2018 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 15 reducing their positions, and 14 closing their positions.
107% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 15
36% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 14
6% more funds holding
Funds holding: 66 → 70 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.23% less ownership
Funds ownership: 57.79% → 56.56% (-1.2%)
58% less capital invested
Capital invested by funds: $246M → $103M (-$144M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$20.4M |
| 2 |
BlackRock
New York
|
+$3.63M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$2.69M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$2.57M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$2.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$19.9M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$5.72M |
| 3 |
First Manhattan
New York
|
-$5.12M |
| 4 |
DM
Deerfield Management
New York
|
-$4.68M |
| 5 |
JP Morgan Chase
New York
|
-$3.81M |
PTGX Hedge Fund Activity: Q1 2018 in Review
70 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q1 2018, worth a combined $103M — down 58% from $246M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new PTGX positions and 14 closed out — a net gain of 5 holders — while 31 added to existing stakes and 15 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $20.4M. The largest seller was Adage Capital Partners, cutting an estimated $19.9M.
- 70 institutional investors held Protagonist Therapeutics (PTGX) as of Q1 2018, up from 66 in Q4 2017.
- Funds reported $103M of Protagonist Therapeutics stock for Q1 2018, down 58% quarter-over-quarter.
- 19 funds opened new Protagonist Therapeutics positions in Q1 2018 and 14 closed out, a net change of +5 holders.
- The largest Protagonist Therapeutics buyer in Q1 2018 was EcoR1 Capital, an estimated $20.4M added.
- The largest Protagonist Therapeutics seller in Q1 2018 was Adage Capital Partners, an estimated $19.9M sold.
Based on aggregated 13F filings for Q1 2018.